Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.
[severe combined immunodeficiency]
For
infants
with
SCID
the
ideal
conditioning
regimen
before
allogeneic
HCT
would
omit
cytotoxic
chemotherapy
to
minimize
short
-
and
long
-term
complications
.
We
performed
a
prospective
pilot
trial
with
alemtuzumab
monotherapy
to
overcome
NK-cell
mediated
immunologic
barriers
to
engraftment
.
We
enrolled
four
patients
who
received
CD
34
-
selected
haploidentical
cells
,
two
of
whom
failed
to
engraft
donor
T
cells
.
The
two
patients
who
engrafted
had
delayed
T
-
cell
reconstitution
,
despite
rapid
clearance
of
circulating
alemtuzumab
.
Although
well-tolerated
,
alemtuzumab
failed
to
overcome
immunologic
barriers
to
donor
engraftment
.
Furthermore
,
alemtuzumab
may
slow
T
-
cell
development
in
patients
with
SCID
in
the
setting
of
a
T
-
cell
depleted
graft
.